Live News • Jul 30
Alamar Biosciences Unveils NULISAseq Immune 340 Panel for Expanded Disease Research Alamar Biosciences launched the NULISAseq Immune 340 Panel, its broadest multiplexed immune profiling product so far, enabling measurement of about 340 immune-related proteins from a single sample for translational research and drug development.
The new panel extends the earlier NULISAseq Inflammation Panel 250 and is aimed at research in cancer, cardiovascular and metabolic diseases, autoimmune conditions, and aging. This broadens the range of disease areas addressable on Alamar’s platform.
Alamar Biosciences shares recently traded at about US$24.37, with the stock down roughly 12.2% over the past 30 days.
This launch signals that Alamar Biosciences is investing in a wider suite of immune proteome tools, which could deepen adoption among researchers focused on complex disease biology. From an investment perspective, a richer panel may help the company capture more workflows within existing customers and appeal to new labs that need high-plex immune profiling, although actual commercial traction and pricing will be important factors to monitor. Announcement • Jul 29
Alamar Biosciences Launches NULISAseq Immune 340 Panel For Comprehensive Profiling Of The Immune Proteome Alamar Biosciences, Inc. announced the launch of the NULISAseq Immune 340 Panel, its broadest multiplexed immune profiling solution available for translational research and drug development. The panel expands on the NULISAseq Inflammation Panel 250, to deliver simultaneous measurement of approximately 340 immune-related proteins from a single sample. By measuring key proteins that were previously undetectable by other methods, the Immune 340 Panel deepens the understanding of the immune proteome in critical disease areas across cancer, cardiovascular and metabolic diseases, autoimmune diseases, and aging research. Highly sensitive multiplex measurement captures regulatory proteins, like checkpoint inhibitors, and low abundance targets that standard platforms routinely miss. Immune responses are never driven by a single protein. Pathway crosstalk, feedback loops, and cell type cooperation all demand multi-protein context to interpret. Understanding this biology, and catching it early, requires measuring the cytokines and other biomarkers of immune activation that signal disease before symptoms appear. The challenge is detection. Many immune mediators, including cytokines, chemokines, and cell death pathway markers, circulate at fg/mL to sub-pg/mL concentrations, well below the floor of conventional immunoassays. This is especially true of inflammaging, the chronic, low-grade inflammation that builds quietly with age as immune senescence and neuroimmune activation compound to drive cardiovascular, metabolic, neurodegenerative, and cancer risk. Its key signals have largely been invisible to researchers until now. In drug development, the ability to simultaneously profile the full immune landscape – not just the well-characterized cytokines, but the entire network of checkpoints, metabolic regulators, cell death mediators, and co-stimulatory signals – fundamentally changes what can be learned from a single sample. What makes the NULISAseq Immune 340 Panel distinctive is the combination of breadth and sensitivity. Many of the proteins most relevant to immune mechanisms of action, resistance, and toxicity have historically been undetectable in blood. Having access to them, alongside the canonical markers, in one multiplexed run opens new possibilities for biomarker discovery and patient stratification. Live News • Jul 25
Alamar Biosciences Secures Rights to Use pTau217 Antibody in Alzheimer’s Diagnostics ALZpath and Alamar Biosciences have expanded their agreement to cover clinical diagnostics, granting Alamar commercial rights to use ALZpath’s proprietary pTau217 antibody in blood-based tests intended for Alzheimer’s disease diagnosis.
The broadened deal allows Alamar to apply the pTau217 antibody in both research and clinical environments, which could support wider use of blood biomarkers as an alternative to more invasive or complex Alzheimer’s diagnostic tools.
Alamar Biosciences’ stock trades at $25.88, with the share price up 17.6% year to date.
Bringing a clinically focused pTau217 antibody into Alamar Biosciences’ test line-up could strengthen its position in Alzheimer’s diagnostics, but it also raises execution questions around assay performance, regulatory pathways and eventual clinical uptake that readers may wish to factor into their risk view. 
